Clinical Trial

Digital Monitoring of Self-reported Symptoms by Patients Treated With Cabozantinib Plus Nivolumab for Advanced Clear-cell Renal Carcinoma

Study acronym: CANIQOL
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The aim of the study is to evaluate the impact of digital monitoring of self-reported symptoms (PROs) on the adjustment of treatment management in patients treated with cabozantinib plus nivolumab for advanced clear cell renal cell carcinoma (RCC) in real life during the first 3 months of combined treatment
Protocol Amendment History 1 change
notable Trial sites expanded: 16 -> 19 locations 2026-07-15
Trial Details
NCT Number NCT07028125
Lead Sponsor Centre Francois Baclesse
Conditions Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally Advanced
Enrollment 83 participants
Start Date 2025-10-01
Primary Completion 2028-10 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-14